Searchable abstracts of presentations at key conferences in endocrinology

ea0056p834 | Pituitary - Clinical | ECE2018

Two cases of silent corticotroph adenomas

Cinel Murat , Canlar Sule , Gullu Sevim

Introduction: Pituitary adenomas are mostly benign tumors which may be clinically functioning or non-functioning and ACTH secreting tumors make up 15% of them. Up to 20% of corticotroph adenomas which don’t have any biochemical or clinical evidence of hypercortisolism are known as silent corticotroph adenomas.Case 1: A 54 years old male presented with blurred of vision and headache that increasing in severity within six years. Physical examination a...

ea0049ep1059 | Pituitary - Clinical | ECE2017

What should central diabetes insipidus and panhypopituitarism point out in a patient with lung adenocarcinoma in remission?

Canlar Sule , Keskin Caglar , Canpolat Asena Gokcay , Gullu Sevim , Corapcioglu Demet

Objectives: Pituitary gland is an uncommon site for metastasis of malignant tumors. Breast and lung are the most common cancer sites. Most pituitary metastases are asymptomatic, with only 7% symptomatic and central diabetes insipidus is the most common symptom.Case presentation: A 54 year-old woman presented with nause, emesis and diplopia to emergency department. Her relatives stated that she had poliuria, nocturia, polidipsia for three months. Her hist...

ea0049ep1487 | Thyroid (non-cancer) | ECE2017

Development of hypoparathyroidism due to targeted therapies

Gokcay Canpolat Asena , Aydogan Berna Imge , Canlar Sule , Gullu Sevim , Erdogan Murat Faik

Due to inhibition affect on proliferation, motility, resistance to apoptosis and growth of metastasis, the epidermal growth factor receptor (EGFR) inhibitor erlotinib and vascular endothelial growth factor receptor (VEGF) and EGFR inhibitor vandetanib are viable treatment options for treatment of advanced non-small cell lung cancer and thyroid cancer respectively. Advanced non-small cell lung carcinomas (NSCLC) or medullary and differentiated thyroid carcinomas (MTC and DTC) m...

ea0041ep254 | Clinical case reports - Pituitary/Adrenal | ECE2016

Bilateral adrenal mass mimicking adrenocortical carcinoma

Canlar Sule , Idemen Celal , Yalci Aysun , Azap Alpay , Faik Erdogan Murat

Introduction: Bilateral adrenal mass presents a unique diagnostic challenge and carries additional risk of being metastasis. The differential diagnosis of bilateral adrenal mass include primary or secondary neoplastic disorders (adrenocortical carcinoma, lymphoma, metastases), pheochromocytoma, longstanding congenital adrenal hyperplasia and macronodular adrenal hyperplasia, infections such as tuberculosis, histoplasmosis and blastomycosis.Case: Thirty-f...

ea0056p430 | Diabetes complications | ECE2018

Characteristics of diabetic foot patients admitted to department of endocrinology and metabolic diseases at ankara university, faculty of medicine

Canlar Sule , Cinel Murat , Mutlu Adile Begum Bahcecioglu , Emral Rifat , Bayram Dilek , Metinarikan Nuran , Yurdakul Birgul , Demir Ozgur , Corapcioglu Demet

Introduction: Diabetic foot is one of the important and destructive complications of diabetes. During the life time of a diabetic patient, the risk of developing foot ulcers is around 5–15%, and about 20–25% of the causes of hospitalization in diabetic patients are due to foot ulcers. 40–80% of foot ulcers can be infected and resulted in osteomyelitis. Hospitalization due to osteomyelitis is 12 times more in diabetic patients than in non-diabetic population....

ea0037ep823 | Pituitary: clinical | ECE2015

Clinical features and treatment outcomes of resistant acromegaly patients: a single-centre study

Demir Ozgur , Canpolat Asena Gokcay , Aydogan Berna Imge , Keskin Caglar , Canlar Sule , Sahin Mustafa , Emral Rifat , Gullu Sevim , Gedik Vedia Tonyukuk , Uysal Ali Riza , Corapcioglu Demet

Introduction: Disease control in acromegaly can be achieved by surgery, medical treatment, and radiotherapy either alone or in combination. The acromegaly patients whom tumour shrinkage cannot be provided or growth hormone levels do not decrease under multiple treatment modalities are designated as resistant acromegaly. We aimed in our study to evaluate the clinical features of resistant acromegaly patients and determine their responds to different treatment modalities.<p ...

ea0049ep967 | Pituitary - Clinical | ECE2017

Is there a role of immunohistochemical expression of pituitary hormones and proliferative marker ki-67 on long-term outcome in our acromegalic patients?

Sahin Mustafa , Keskin Caglar , Kiremitci Saba , Erden Esra , Canpolat Asena , Cinel Murat , Canlar Sule , Demir Ozgur , Gullu Sevim , Emral Rifat , Erdogan Murat Faik , Gedik Vedia , Baskal Nilgun , Corapcioglu Demet

Expression of hormones other than GH may affect the prognosis in acromegalic patients. Generally, Ki-67 is a well-known proliferative index used to predict remission in pituitary adenomas. We aimed to evaluate the relationship of immunohistochemical expression pituitary hormones, ki-67 and remission. Also we evaluated the role of pre, post-operative clinical and laboratory values, pathological characteristics on long-term remission. We included 64 acromegaly patients that were...